iiinova — where your digital self keeps evolving

Fareon Announces New Paper Linking Biomarkers for Lower Predicted Brain Age, Reduced Inflammation, and Activation of Repair to Its Noninvasive Biophysics Treatment

fantastic team from Fareon - these analyses are tricky and the amount of data are overwhelming. Our team is incredibly fortunate to have such great collaborators that are pushing urgently for this technology to be accessible to patients ASAP. Onward! www.globenewswire.com/news-release... /end

globenewswire.com

Plasma proteomics data reveal biological changes in people receiving Fareon Restore™ at home, supporting the potential to treat brain disorders through...

081

test this technology in other diagnoses where we believe neuroinflammation to be driving cognitive symptoms: #concussion, #TBI, #stroke, #mecfs and chronic #lyme. These are incredibly promising results and I'm so grateful to the brilliant team at SomaScan as well as the 9/

1131

from non-responders (NR). We have a long way to go before this is an approved treatment for cog impairment in people with #LongCOVID, but the next phase of this project is to initiate a large-scale, multi-site clinical trial of this technology. In parallel, we are starting to 8/

180

Proteins involved in things like increasing autophagy, reducing inflammation, boosting mitochondrial function and these 17 proteins really popped in the analysis that was done by the team, with a 17-protein response score clearly physiologically differentiating MMT responders 7/

Heat map and box plots showing that the 17 proteins of interest are more active in the MMT responders than any other group

190

That really appeared to be associated with clinical response to the MMT therapy (figure below). What was particularly cool about these proteins was that they weren't 'junk' proteins, they were proteins that were legitimately associated with the MMT mechanism of action. 6/

Flow chart showing the breakdown of over 10,000 proteins measured to 17 core "responder" proteins.

170

First finding of note was the responder analysis: encouragingly, in our cohort from the first paper we saw many more responders (R) in the treatment group than the sham group (80% vs. 30%). But then as we dug into the proteomics, we noted that there were 17 different proteins 5/

A graph showing responder vs. non-responder rates in sham vs MMT trial groups. The responder rates in the MMT group is 80% vs. only 30% in the sham group

150

Somascan uses synthetic DNA probes as molecular detectors, this method can precisely measure over 10,000 proteins simultaneously in blood plasma. This technique is very sensitive to changes in protein expression between timepoints that may be driving improvements in symptoms. 4/

150

Plasma Proteomics Identifies a Microtesla Magnetic Therapy Response Signature in Long COVID

control arm. What was cool about this study was that we also captured plasma at different stages of the trial and in collaboration with Somascan #proteomics, we took a look at differences in proteomic readout in the MMT trial participants (preprint👇) www.medrxiv.org/content/10.6... 3/

medrxiv.org

Cognitive impairment is a disabling feature of Long COVID with no established disease-modifying therapy, and little is known about the biological changes accompanying clinical improvement. Microtesla ...

170

controlled pilot, we showed that MMT was a well-tolerated and feasible intervention that could be deployed remotely in the home. In addition to this, we saw some early signal that it may also be having an effect on patient cognition in the active treatment arm vs. those in the 2/

170

Microtesla Magnetic Therapy for cognitive impairment in post-acute sequelae of SARS CoV-2: A randomized controlled feasibility study

Delighted to announce some new progress on our #LongCOVID trial with Fareon and their first-in-human microtesla magnetic therapy (MMT) device. As you may recall, we pre-printed the safety/feasibility work not too long ago: www.medrxiv.org/content/10.6... In this triple-blind placebo- 1/

medrxiv.org

Background Cognitive impairment has significant implications for function and quality of life and is common in individuals with post-acute sequelae of SARS CoV-2, also known as long COVID (LC). Emergi...

35913

However, I hope this megathread adequately explains my position and I hope that people can understand that my team’s North Star is always working rapidly to make more viable treatment options available for people suffering with these terrible diagnoses. Keep up the fight 💪🏼 /end

6470

to budge. There is a lot of work to be done and we get there much faster together. Also apologies for the length of this and for the fact that I’ve pretty much used up my entire social media allowance for the week on writing this monster so I’m unlikely to respond to much… 36/

1250

are no other valid viewpoints” probably isn’t seeing the issue clearly at the moment. We need people of differing viewpoints to come together and to be willing to discuss literature, concede issues and move the field forward rather that digging into one position and refusing 35/

reactivated or worsened chronic #lyme disease from a #COVID infection. You get the point. This is a complex space and answers won’t come easily. Also, we don’t have any reason to have certainty in these ideas just yet. Anyone who tells you “this is the way it should and there 34/

1201

you roll up your sleeves and get to work in making the most specific diagnosis that you can: #LongCOVID, #MECFS, chronic #lyme, babesiosis, #EDS, #sjogrens, #hashimotos, #MECFS that has been worsened by a COVID infection, #LongCOVID AND #MECFS, reactivated EBV from a COVID, 33/

1242

PAIS and IACCI may seem like “lumper mindset”, but the first step to splitting appropriately is creating a common framework from where you start to split. In my mind, that’s what PAIS/IACCI is: once you suspect that this is the diagnostic cluster that you’re working within, 32/

1233

going to pause and state: this is my opinion. Other opinions are valid, but in clinical practice and science we often talk about “lumpers” and “splitters”. I’m a splitter. I want to understand distinct differences and treat specific physiological problems. I understand that 31/

1200

have far better tools and the ability to implement them much faster if we move together with focused purpose. However, the way that we get there, in my opinion, is by understanding the differences between these diagnoses and targeting those differences aggressively. Again I’m 30/

personality” (as Sontag wrote about in 1978) to precision medicine approaches for every type of cancer we have a name for. I firmly believe that this level of progress is possible for diagnoses that exist under the IACCI/PAIS umbrella, and hopefully much, much faster as we 29/

1343

miss one. These red flags are general: they don’t differentiate cancers, but they do raise the alarm and allow you to get precision treatments ASAP. From the 1970s to 2026, we have gone from people being told they’re getting certain types of cancer because of a “cancer 28/

1241

is DOABLE. This was done in cancer. Anyone with any clinical training learns about “red flags” for cancer: these are symptoms that should trigger an alarm in any clinician if they occur alongside other signs and symptoms. Cancer red flags are drummed into us so that we never 27/

1241

Continuing this mega-thread. At tweet 25, I had just shared my dream of what an ideal IACCI diagnostic process would look like. Although it might seem far-fetched or aspirational to some (and hopefully very common sense and doable to many others), what history shows us is it 26/

1181

perhaps it is Frances Eun Hyung-Lee's MENSA test for EBV reactivation, or maybe it is a good "old-fashioned" iGeneX Babesia FISH test, but the PCP gets to the bottom of what it is, makes the distinct diagnosis and then provides the targeted therapy. Wow. Long thread. TBC... 25/

1302

moonshot goal is that one day, when a sick person walks into a PCP's office with symptoms that are common to many IACCIs, the PCP is able to conduct a battery of tests: maybe it is a PET scan after an infusion with Tim Heinrich's radioligand that binds to SARS-CoV-2 spike, 24/

1284

showing similarities in immune dysregulation, pathogen reactivation, metabolomic, vascular and neurological changes in many IACCIs. However the more we study them together, the more we also see subtle but distinct differences amongst the different diagnoses. To be clear: my 23/

1201

chronic #lyme and other tick-borne illnesses as well as similar improvements in provider belief in the legitimacy of these diagnoses. From a research side, I find these frameworks helpful because we know that the pathobiological landscape holds overlap. We see many papers 22/

providers with a framework to understand that infections can cause long-term consequences. And it appears to work: after our sessions, we're seeing twofold and threefold improvements in self-reported provider readiness to identify distinct diagnoses like #LongCOVID, #MECFS or 21/

1280

to notice that something wasn't right? What was happening at that time? Did you get sick (maybe COVID)? Something that felt like food poisoning (maybe enterovirus)? Any chance you were bitten by a tick (tick-borne illness) or scratched by a cat (bartonella)? Equipping 20/

1260

clinical journey is where we're encouraging PCPs to "think IACCI". This is where we explain what these illnesses are and how they have distinct features even though some of their symptoms may overlap. We teach them about questions to ask - what was the point where you started 19/

1270

the blood tests that the PCPs know to run in situations like this come back normal. In 99% of clinical realities this would then open the door to a referral to psych, discussion of stress at work and home, etc. This is where we are trying to change things. THIS POINT in the 18/

2361

what, in fact, usually happens is that a person presents to the clinic reporting fatigue, struggling at work (or being unable to work), migraine, cognitive impairment, heart palpitations, GI disturbances, (...you all know these symptoms by heart so I won't keep going) but all 17/

1232

Unfortunately, in 2026 the clinical reality is that most patients don't show up to a primary care practitioner (PCP) with a positive COVID test from 8 months ago, telling them about Long COVID symptoms. From focus group work we (and others) have done with thousands of PCPs 16/

1244

after identifying that a patient has an IACCI. Why is this important? Because we're trying to teach first-line clinical providers to identify suspected PAIS/IACCI in the clinic. This means we take several steps back and try to understand the experience of a newly ill person. 15/

1200

Manual — The Cohen Center for Recovery from Complex Chronic Illness

whilst allowing them to also appreciate the differences. As you will note in our *free* educational materials (coresinai.org/manual) as well as any number of online CME-accredited talks I've given in the last 4 years or so. We talk about how to make DISTINCT diagnoses 14/

coresinai.org

1170

in the hopes that we can see that this can be helpful when used appropriately. From an educational perspective, I like constructs such as PAIS and IACCI because they allow us to teach clinical providers and researchers about physiological commonalities between diagnoses 13/

2221

renamed to Hepatitis C. I like this example specifically because it shows clinicians and researchers wrestling with a condition that looked like the others but they knew it wasn't. Then they did the science to figure it out and named it appropriately. I'm sharing the history 12/

1240

Hepatitis A, Hepatitis B and Non-A, Non-B Hepatitis (NANBH). They knew that NANBH looked like and acted like Hep A and Hep B but wasn't. So they named it NANBH. When they learned of the pathogen that causes NANBH (a flaviviridae imaginatively named "Hepatitis C Virus"), they 11/

1200

The acronyms changed because the science changed: we learned that there was more to separating these illnesses out than simply whether or not a person with a diabetes diagnosis required insulin to survive. Similarly, the world of hepatitis had the branches from 1975-1989: 10/

worth noting that the acronym-ification of illnesses is kind of how medicine works, historically: Diabetes did it: We went from Insulin-Dependent and Non-insulin-dependent diabetes mellitus (IDDM and NIDDM) from 1979-1997 before they were changed to Type-1 and Type-2 Diabetes. 9/

1241

we noted that, globally, there were efforts to create phrases to describe some of these diagnoses collectively - PAIS and IACCI are the most prominent. Others, e.g. Infection Associated Chronic Conditions (IACC), Infection-Associated Chronic Illnesses (IACI) also exist. It is 8/

1180

observations made by my team and others that may or may not be correct. I'm very open to people changing my mind on these topics, but so far this is where my opinion, and it is opinion NOT fact, sits. Ok. Pause over. My team was seeing and studying many of these diagnoses and 7/

1210

persisted or reactivated, chronic inflammation, immune dysregulation, joint hypermobility across diagnoses and so it made sense to us to see each of these DISTINCT but *potentially* INTER-RELATED diagnoses. I'm going to pause here and remind people again - these are 6/

1300

not "cure". Though we hope to be able to do both one day. The decision to treat more of these conditions than just becoming a dedicated chronic #Lyme or #LongCOVID center was intentional: we were noting a similarity in certain aspects of physiological changes, pathogens that 5/

1292

Ok, so let's get into it: As many of you know, I am the Director of a center that treats #LongCOVID, #MECFS, chronic #Lyme and hypermobility spectrum disorders. At this stage in our learning and evolution, I can say that in the majority (90-95%) of cases, we "treat" and we do 4/

1324

state that although I don't think that PAIS and/or the US variant that has been endorsed by Health and Human Services (HHS) "Infection-Associated Chronic Conditions and Illnesses" (IACCI) are perfect, I think that they serve a purpose and are likely to change in the future. 3/

1202